Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (Nasdaq: EOLS) has announced a proposed underwritten public offering of its common stock, subject to market conditions. The company may grant underwriters an option to purchase an additional 15% of shares. The net proceeds will fund the growth of Jeuveau® in the U.S., support European pre-launch activities, and cover general corporate purposes. This offering is managed by SVB Leerink, Stifel, and Cantor. Details are available in the preliminary prospectus supplement filed with the SEC.
Evolus, a performance beauty company, reported a strong Q4 2020 with net revenue of $20.6 million, its highest since launching Jeuveau®.
The company resolved significant litigation issues, eliminating $127 million in debt, and improved its cash position to $57 million as of December 31, 2020. Despite litigation expenses impacting operating results, gross margins were solid at 64.6% for Q4. The company expects net revenue to continue rising in 2021, despite short-term gross margin pressures due to settlement agreements.
Evolus, Inc. (NASDAQ: EOLS) will report its fourth quarter and year-end 2020 financial results on March 24, 2021. The company will hold a conference call at 4:30 p.m. ET to discuss these results and provide a business update. A question and answer session will follow management remarks. Domestic callers can dial (866) 916-2317, while international callers should use (703) 925-2662, with a conference ID of 7378855. A replay will be accessible until March 31, 2021. A live audio webcast will be available on the Evolus investor relations page and archived for 30 days.
Evolus, Inc. (Nasdaq: EOLS) announced a significant financial restructuring with Daewoong Pharmaceutical, enhancing its balance sheet. The settlement includes a $25.5 million cash payment, the elimination of $127.4 million in debt and milestone payments, and the conversion of $40.5 million in debt into approximately 3.1 million shares. This leaves Evolus with a pro forma cash position of $57 million as of December 31, 2020. The company aims to drive growth for its neurotoxin product Jeuveau® and expand internationally with the launch of Nuceiva™ in early 2022.
Evolus, a performance beauty company, announces participation in two virtual investor conferences. The first event is the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, featuring a fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference on March 10, 2021, with a presentation scheduled from 1:15 PM to 1:40 PM ET. Audio webcasts will be accessible on Evolus' investor relations website, with replays available for 90 days post-presentation.
Evolus, Inc. (Nasdaq: EOLS) has promoted Crystal Muilenburg to Chief Marketing Officer, effective immediately, enhancing its marketing leadership. Muilenburg brings over 20 years of experience, particularly in aesthetics from her time at Allergan. David Moatazedi, CEO, emphasized the company’s growth trajectory post-ITC legal case, focusing on expanding Jeuveau® sales and international presence. Concurrently, Michael Mazen Jafar will leave his position as Chief Commercial Officer to pursue another opportunity. Evolus is poised for significant market expansion.
Evolus, Inc. (NASDAQ: EOLS) reported preliminary net revenues of $20.6 million for Q4 2020, marking a 16% increase over Q3 2020. For the entire year, the company achieved $56.5 million in total revenue, driven primarily by Jeuveau® sales. The company also noted an expansion to over 5,600 ordering accounts and a record re-order rate of 71.6% in Q4. Legal matters, including a case with Abbvie and Medytox, were resolved, and while pricing increased during the ITC review period, actual revenue was nominal during that timeframe.
Evolus, a performance beauty company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. The event will feature a fireside chat and one-on-one meetings from 1:00 PM to 1:30 PM ET. An audio webcast of the chat will be available on Evolus' investor relations website, with replays accessible for 90 days. Evolus is known for its innovative products, including Jeuveau®, a neurotoxin dedicated to aesthetics, approved by the FDA in 2019.
AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS), and Medytox have settled all litigation related to Jeuveau®, resolving a case filed by Medytox against Evolus. Under the agreement, AbbVie and Medytox release claims against Evolus and allow the commercialization of Jeuveau® in the U.S. and Nuceiva™ elsewhere. Evolus will pay milestone and royalty fees and issue stock to Medytox. This settlement follows an ITC decision from December 16, 2020, that found misappropriation of Medytox's trade secrets but does not affect ongoing legal matters with Daewoong.
Evolus, Inc. (NASDAQ: EOLS) announced the U.S. International Trade Commission (ITC) partially affirmed a Section 337 violation against the company regarding the Jeuveau® product. The ITC has imposed a 21-month ban on the import, sale, and marketing of Jeuveau® in the U.S., a reduction from the ALJ's proposed 10-year ban. Evolus plans to post a bond to continue sales during the 60-day presidential review period. CEO David Moatazedi expressed commitment to overturning the ITC decision and thanked stakeholders for their support.